Our Leadership Team

Dr. Baudry is an internationally known neuroscientist with over 350 publications and is one of the 100 most cited neuroscientists in the world. He is the Dean, Graduate College of Biomedical Sciences at Western University of Health Sciences and former professor of biological sciences, neurology and biomedical engineering at University of Southern California. Dr. Baudry graduated from Ecole Polytechnique in Paris and earned a PhD in biochemistry at University of Paris VII under the direction of professors J.C. Schwartz and J.P. Changeux, two of France’s most distinguished neurobiologists.

Dr. Baron is a leading authority on traumatic brain injuries and has led cutting edge concussion research funded by the NFL.. Dr. Baron is currently Senior Vice President and Provost of the Western University of Health Sciences. Dr. Baron joined the university in May 2018 after serving for eight years in roles within the Department of Psychiatry at the Keck School of Medicine, including Vice Dean for Global Health, Professor of Psychiatry and Neurosurgery, Vice Chair of the Department, and Chief of Service at Keck-USC Hospital.He received his DO degree from the Philadelphia College of Osteopathic Medicine (PCOM) and a Master of Science in Education from the University of Southern California (USC). He is the former Deputy Clinical Director of the National Institute of Mental Health (NIMH), former President of the American College of Neuropsychiatry and the Group for the Advancement of Psychiatry, and chaired the Department of Psychiatry at Temple University School of Medicine from 1998-2010.Dr. Baron was named a National Fulbright scholar in 2017-18 and conducted his research as Distinguished Chair in Brain Research at the University of Calgary. He also is the recipient of a Fulbright Specialist Award for 2016-21.

Dr. Palfreyman is an internationally recognized leader in neurological drug development with a successful scientific and business career spanning 35 years. He brings to NeurAegis a distinguished track record of successful drug development and considerable expertise in CNS pharmacology, pharmacogenomics and rational drug design. Dr. Palfreyman’s broad perspective on drug development derives from his experience as Chief Scientific Officer for Amorsa Therapeutics and President and CSO of Psychiatric Genomics; Senior Scientific Advisor to EnVivo Pharmaceuticals and Vitruvean; co-founder of NOVACE; Senior VP for Research and Development at Anadys (formerly Scriptgen); as well as senior executive and scientific leadership roles at Marion Merrell Dow (Sanofi-Aventis) and Beecham (GlaxoSmithKline). In these roles, he successfully developed and demonstrated clinical efficacy of several candidates across multiple therapeutic areas. Dr. Palfreyman holds Ph.D. and D.Sc. degrees and is a member of the Royal Pharmaceutical Society. He continues to be an active scientific contributor with more than 150 publications and 35 issued patents.